Vor Biopharma Inc. (VOR) Stock: Price, Forecast & Analyst Target
Vor Biopharma Inc. (VOR) — MoonshotScore 66/100 (Strong band), calculated Nov 18, 2026. Price $18.52 (+3.87%), as of the Nov 19, 2026 trading session; market cap $1.14B.
Educational signal · not a buy or sell recommendation · How to read this
Vor Biopharma Inc. · VOR · NASDAQ
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell (eHSC) therapies.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Vor Biopharma (VOR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, at a cheap price, but weak growth; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Fading; Momentum: Surging.
- EPS beat 1 of the last 4 reports
- Altman Z 6.83 · Piotroski F 3
Holding back: soft growth
Helping: balance-sheet strength, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 60 | Fair | |
| 60 | Fair | |
| 60 | Fair | |
| 60 | Fair | |
| 66 | Strong | |
| 66 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $18.52 | |
| Change on the day | +3.87% | |
| 52-week range | $6.50 – $26.00 | |
| Market capitalisation | $1.14B | — |
| Price / earnings (trailing) | 0.06 | |
| Shares traded on the day | 825.9K |
Price & events
Other perspectives
Council score for Vor Biopharma (VOR): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Vor Biopharma (VOR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Vor Biopharma Inc. (VOR) is listed on NASDAQ. It employs 76 people and is led by Jean-Paul Kress. The market values it at $1.14B.
What do the latest results show for Vor Biopharma (VOR)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
What are the financial strengths and risks for Vor Biopharma (VOR)?
Short answer
The MoonshotScore pillars rate balance-sheet strength, an attractive price, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 6.83 · Piotroski F 3. Trailing ratios: ROA -27.5% · current ratio 13.50.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Vor Biopharma (VOR)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $4.17M · EPS -8.08 · 8 analysts. Current published price targets run low $27.00 · high $40.00 · consensus $33.50 · median $33.50 against a quoted price of $18.52 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for VOR.
Checked against the records this page reads, on the dates shown above.
How does Vor Biopharma compare with its peers?
Short answer
Vor Biopharma's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $33.11 Nov 18, 2026 | $1.94B | 96 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| Vor Biopharma (VOR) — this page | $18.52 | $1.14B | 66 |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $13.72 Nov 19, 2026 | $1.96B | 63 5-pillar Nov 18, 2026 | |
| $26.51 Nov 19, 2026 | $1.06B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $27.00 – $40.00
- Consensus target
- $33.50
- Median target
- $33.50
- Revenue estimate
- $4.17M
- EPS estimate
- $-8.08
Consensus record · Captured .
Measured against a quoted price of $18.52 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 2, 2026
- Transactions
- 17
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 1
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VOR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VOR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Vor Biopharma (VOR)?
- Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
- Vor Biopharma Adds RC298 to RemeGen License Deal
- Vor Bio Amends Agreement with RemeGen to Include RC298
- Vor Bio Announces Amended RemeGen License Adding Autoimmune Drug Candidate RC298 For ~$56M Upfront In Cash And Warrants, Up To $300M In Milestones
What Investors Ask About Vor Biopharma (VOR)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for VOR?
VOR carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is VOR a good stock to buy?
Stock Expert AI does not rate VOR buy, sell or hold. Vor Biopharma Inc. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VOR stock price today?
The last price recorded for Vor Biopharma Inc. (VOR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the VOR price target?
The analyst consensus price target for Vor Biopharma Inc. (VOR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for VOR?
Vor Biopharma Inc. (VOR) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Vor Biopharma has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. Not financial advice.
How frequently does VOR data refresh on this page?
VOR's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VOR's recent stock price performance?
Vor Biopharma Inc. (VOR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative eHSC technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VOR overvalued or undervalued right now?
The trailing P/E of Vor Biopharma Inc. (VOR) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of VOR?
Fractional-share availability for Vor Biopharma Inc. (VOR) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 11 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com